Interaction between moxifloxacin and Mcl-1 and MITF proteins: the effect on growth inhibition and apoptosis in MDA-MB-231 human triple-negative breast cancer cells.
Breast cancer
Cellular homeostasis
In silico analysis
Moxifloxacin
Journal
Pharmacological reports : PR
ISSN: 2299-5684
Titre abrégé: Pharmacol Rep
Pays: Switzerland
ID NLM: 101234999
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
21
12
2021
accepted:
14
08
2022
revised:
10
08
2022
pubmed:
1
9
2022
medline:
25
10
2022
entrez:
31
8
2022
Statut:
ppublish
Résumé
Microphthalmia-associated transcription factor (MITF) activates the expression of genes involved in cellular proliferation, DNA replication, and repair, whereas Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing apoptosis. The objective of the present study was to verify whether the interaction between moxifloxacin (MFLX), one of the fluoroquinolones, and MITF/Mcl-1 protein, could affect the viability, proliferation, and apoptosis in human breast cancer using both in silico and in vitro models. Molecular docking analysis (in silico), fluorescence image cytometry, and Western blot (in vitro) techniques were applied to assess the contribution of MITF and Mcl-1 proteins in the MFLX-induced anti-proliferative and pro-apoptotic effects on the MDA-MB-231 breast cancer cells. We indicated the ability of MFLX to form complexes with MITF and Mcl-1 as well as the drug's capacity to affect the expression of the tested proteins. We also showed that MFLX decreased the viability and proliferation of MDA-MB-231 cells and induced apoptosis via the intrinsic death pathway. Moreover, the analysis of the cell cycle progression revealed that MFLX caused a block in the S and G2/M phases. We demonstrated for the first time that the observed effects of MFLX on MDA-MB-231 breast cancer cells (growth inhibition and apoptosis induction) could be related to the drug's ability to interact with MITF and Mcl-1 proteins. Furthermore, the presented results suggest that MITF and Mcl-1 proteins could be considered as the target in the therapy of breast cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Microphthalmia-associated transcription factor (MITF) activates the expression of genes involved in cellular proliferation, DNA replication, and repair, whereas Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing apoptosis. The objective of the present study was to verify whether the interaction between moxifloxacin (MFLX), one of the fluoroquinolones, and MITF/Mcl-1 protein, could affect the viability, proliferation, and apoptosis in human breast cancer using both in silico and in vitro models.
METHODS
METHODS
Molecular docking analysis (in silico), fluorescence image cytometry, and Western blot (in vitro) techniques were applied to assess the contribution of MITF and Mcl-1 proteins in the MFLX-induced anti-proliferative and pro-apoptotic effects on the MDA-MB-231 breast cancer cells.
RESULTS
RESULTS
We indicated the ability of MFLX to form complexes with MITF and Mcl-1 as well as the drug's capacity to affect the expression of the tested proteins. We also showed that MFLX decreased the viability and proliferation of MDA-MB-231 cells and induced apoptosis via the intrinsic death pathway. Moreover, the analysis of the cell cycle progression revealed that MFLX caused a block in the S and G2/M phases.
CONCLUSIONS
CONCLUSIONS
We demonstrated for the first time that the observed effects of MFLX on MDA-MB-231 breast cancer cells (growth inhibition and apoptosis induction) could be related to the drug's ability to interact with MITF and Mcl-1 proteins. Furthermore, the presented results suggest that MITF and Mcl-1 proteins could be considered as the target in the therapy of breast cancer.
Identifiants
pubmed: 36045272
doi: 10.1007/s43440-022-00407-7
pii: 10.1007/s43440-022-00407-7
pmc: PMC9585003
doi:
Substances chimiques
Moxifloxacin
U188XYD42P
Microphthalmia-Associated Transcription Factor
0
MITF protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1025-1040Subventions
Organisme : Śląski Uniwersytet Medyczny
ID : PCN-1-097/K/0/F
Organisme : Śląski Uniwersytet Medyczny
ID : PCN-1-041/N/1/F
Organisme : Śląski Uniwersytet Medyczny
ID : PCN-1-090/N/1/F
Organisme : Śląski Uniwersytet Medyczny
ID : PCN-1-091/N/1/F
Organisme : Śląski Uniwersytet Medyczny
ID : PCN-2-048/K/1/F
Informations de copyright
© 2022. The Author(s).
Références
FEBS Lett. 2010 Jul 16;584(14):2981-9
pubmed: 20540941
Bioorg Med Chem Lett. 2011 Mar 15;21(6):1802-6
pubmed: 21316236
Lab Invest. 2017 Jun;97(6):649-656
pubmed: 28263292
Bioorg Med Chem. 2019 Jul 15;27(14):3005-3060
pubmed: 31182257
Cancer Treat Rev. 2018 Jan;62:110-122
pubmed: 29202431
Pharmacol Rep. 2018 Feb;70(1):6-13
pubmed: 29306115
PLoS One. 2015 Apr 24;10(4):e0125010
pubmed: 25909780
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
J Med Chem. 2013 Jan 10;56(1):15-30
pubmed: 23244564
Biochim Biophys Acta. 2011 Jun;1807(6):735-45
pubmed: 21453675
Biochem Pharmacol. 2008 Mar 15;75(6):1272-81
pubmed: 18191106
Bioorg Med Chem Lett. 2014 Mar 15;24(6):1484-8
pubmed: 24582986
Proteins. 2009;77 Suppl 9:114-22
pubmed: 19768677
Mol Oncol. 2007 Sep;1(2):172-80
pubmed: 19383293
Oncotarget. 2015 Mar 30;6(9):7195-208
pubmed: 25749517
Int J Oncol. 2010 Aug;37(2):463-71
pubmed: 20596674
FASEB J. 2018 May 29;:fj201800120R
pubmed: 29812973
Toxicol In Vitro. 2020 Aug;66:104884
pubmed: 32437906
Cancer Lett. 2017 Nov 28;409:116-124
pubmed: 28923400
J Exp Clin Cancer Res. 2011 Sep 26;30:87
pubmed: 21943236
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Genes Dev. 2012 Dec 1;26(23):2647-58
pubmed: 23207919
BMC Cancer. 2015 Aug 11;15:581
pubmed: 26260159
Cell Death Dis. 2018 Jan 16;9(2):19
pubmed: 29339815
Antimicrob Agents Chemother. 2011 Feb;55(2):649-58
pubmed: 21135179
Toxicol In Vitro. 2019 Mar;55:75-92
pubmed: 30528372
Int J Mol Sci. 2018 Feb 02;19(2):
pubmed: 29393886
Drug Saf. 2009;32(5):359-78
pubmed: 19419232
J Invest Dermatol. 2016 Nov;136(11):2277-2286
pubmed: 27427486
Oncogenesis. 2020 Mar 20;9(3):36
pubmed: 32198343
Biomed Pharmacother. 2019 Mar;111:934-946
pubmed: 30841473
Cancer Cell. 2004 Dec;6(6):565-76
pubmed: 15607961
Free Radic Res. 2010 May;44(5):479-96
pubmed: 20370557
Genes Dev. 2006 Dec 15;20(24):3426-39
pubmed: 17182868
Biochem Pharmacol. 2010 Apr 15;79(8):1100-7
pubmed: 20025849
Pathol Oncol Res. 2020 Jul;26(3):1465-1474
pubmed: 31432325
Cancers (Basel). 2011 Mar 11;3(1):1285-310
pubmed: 24212662
Signal Transduct Target Ther. 2017 Apr 07;2:17012
pubmed: 29263915
Int J Mol Sci. 2020 Dec 19;21(24):
pubmed: 33352719
Oncogene. 2011 Jun 23;30(25):2810-22
pubmed: 21317925
Nat Commun. 2018 Dec 17;9(1):5341
pubmed: 30559424
Curr Pharm Biotechnol. 2017;18(2):127-137
pubmed: 27903235
Cancers (Basel). 2021 Jun 11;13(12):
pubmed: 34208068
Eur J Pharmacol. 2018 Sep 15;835:94-107
pubmed: 30086267
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Biochim Biophys Acta. 2012 Oct;1823(10):1767-77
pubmed: 22732297
Breast Cancer (Dove Med Press). 2016 May 20;8:93-107
pubmed: 27284266
Molecules. 2020 Jun 21;25(12):
pubmed: 32575817
Br J Cancer. 2006 Oct 23;95(8):1038-46
pubmed: 17047652